We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CMPS
1301
Compass Pathways
CMPS
$1.46B
$1K ﹤0.01%
+64
New +$2.04K
COGT icon
1302
Cogent Biosciences
COGT
$6.95B
$1K ﹤0.01%
+116
New +$1.01K
COLL icon
1303
Collegium Pharmaceutical
COLL
$1.16B
$1K ﹤0.01%
76
CRIS icon
1304
Curis
CRIS
$9.41M
$1K ﹤0.01%
+1
New +$2.38K
EOLS icon
1305
Evolus
EOLS
$410M
$1K ﹤0.01%
+162
New +$1.11K
EYPT icon
1306
EyePoint Inc
EYPT
$1B
$1K ﹤0.01%
+99
New +$1.33K
GBIO
1307
DELISTED
Generation Bio
GBIO
$1K ﹤0.01%
19
GERN icon
1308
Geron
GERN
$930M
$1K ﹤0.01%
684
HOWL icon
1309
Werewolf Therapeutics
HOWL
$21.8M
$1K ﹤0.01%
+80
New +$1.21K
IMA
1310
ImageneBio Inc
IMA
$65.5M
$1K ﹤0.01%
+9
New +$1.46K
IMRX icon
1311
Immuneering
IMRX
$274M
$1K ﹤0.01%
+76
New +$1.85K
KALV
1312
DELISTED
KalVista Pharmaceuticals
KALV
$1K ﹤0.01%
46
KMDA icon
1313
Kamada
KMDA
$407M
$1K ﹤0.01%
84
KNSA icon
1314
Kiniksa Pharmaceuticals
KNSA
$6.11B
$1K ﹤0.01%
60
KPTI icon
1315
Karyopharm Therapeutics
KPTI
$161M
$1K ﹤0.01%
9
KZR
1316
DELISTED
Kezar Life Sciences
KZR
$1K ﹤0.01%
9
MIRM icon
1317
Mirum Pharmaceuticals
MIRM
$6.84B
$1K ﹤0.01%
+89
New +$1.39K
NRXP icon
1318
NRX Pharmaceuticals
NRXP
$152M
$1K ﹤0.01%
+17
New +$1.23K
OLMA icon
1319
Olema Pharmaceuticals
OLMA
$1.01B
$1K ﹤0.01%
+118
New +$2.44K
OMER icon
1320
Omeros
OMER
$816M
$1K ﹤0.01%
214
PAHC icon
1321
Phibro Animal Health
PAHC
$1.48B
$1K ﹤0.01%
38
PASG icon
1322
Passage Bio
PASG
$14.7M
$1K ﹤0.01%
9
PRLD icon
1323
Prelude Therapeutics
PRLD
$370M
$1K ﹤0.01%
+104
New +$1.69K
QNCX icon
1324
Quince Therapeutics
QNCX
$18.9M
$1K ﹤0.01%
1
RANI icon
1325
Rani Therapeutics
RANI
$92.1M
$1K ﹤0.01%
+58
New +$1.32K

Similar funds

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.